SAU · 4017.SR · SAR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 12:10 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SAR. Historical prices are not a forecast.
Dr. Soliman Abdul Kader Fakeeh Hospital Co.’s quoted price sits in the lower half of its reported 52-week range, 29.23% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Dr. Soliman Abdul Kader Fakeeh Hospital Co.’s forward annual dividend is SAR 0.33 per share, paid annual. The forward yield is 1.09% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Dr. Soliman Abdul Kader Fakeeh Hospital Co.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of SAR 0.22. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Dr. Soliman Abdul Kader Fakeeh Hospital Co.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Dr. Soliman Abdel Kader Fakeeh Hospital Company, together with its subsidiaries, establishes, operates, and manages hospitals, clinics, medical, educational, and training centers in the Kingdom of Saudi Arabia. The company operates through Medical Services; Education; and Trading, Retail & Others segments. It provides various services, such as assisted reproductive therapy, audiology, bariatric surgery, pediatric, breast feeding, cardiac surgery, cardiology, chest and respiratory diseases, chiropractic medicine, dental and maxillofacial, dermatology, otorhinolaryngology, endocrinology, ophthalmology, family medicine, gastroenterology, general surgery, geriatric medicine, hematology, hyperbaric oxygen service, infectious diseases, internal medicine, interventional radiology, psychiatry, lasik surgery, nephrology, neuro surgery, neurology, nutrition, obstetrics and gynecology, oncology, orthopedics, pediatric orthopedic surgery, pediatric surgery, physical medicine and rehabilitation, plastic surgery, rheumatology, sleep disorders clinic, speech therapy, thoracic surgery, urology, and vascular surgery, as well as pain treatment and palliative care services. The company also operates AIRS, anesthesia, burn, diagnostics service, emergency medicine, endoscopy, intensive care, NICU, renal dialysis, rhinoplasty, and institute of robotic surgery facilities; establishes and manages pharmacies; and provides analysis and radiology laboratory, healthcare, medical education, and home health care services. In addition, it engages in the trading of pharmaceutical products, spectacles, and cosmetics; construction and contracting; wholesale and retail of medical equipment; and maintenance of IT equipment and software related services. The company was incorporated in 1978 and is based in Jeddah, the Kingdom of Saudi Arabia.
Latest available per-share figures in SAR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 02:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 12, 2025 |
| SAR 0.31 |
| SAR 701.02M |
| Q4 2024 | Mar 5, 2025 | SAR 0.32 | SAR 2.79B |
|---|
| Q3 2024 | Nov 7, 2024 | SAR 0.44 | SAR 713.82M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SAR 221.50-SAR 1.60 (-0.72%)
Dr. Sulaiman Al Habib Medical Services Group Company’s quoted price sits in the lower half of its reported 52-week range, 18.57% below the high.
SAR 55.20-SAR 0.40 (-0.72%)
Mouwasat Medical Services Company’s quoted price sits in the lower half of its reported 52-week range, 29.23% below the high.
SAR 64.95-SAR 0.65 (-0.99%)
Dallah Healthcare Company’s quoted price sits in the lower half of its reported 52-week range, 49.09% below the high.
SAR 102.10+SAR 3.50 (+3.55%)
National Medical Care Company’s quoted price sits in the lower half of its reported 52-week range, 42.87% below the high.
SAR 21.43-SAR 0.07 (-0.33%)
Al Hammadi Holding Company’s quoted price sits in the lower half of its reported 52-week range, 38.81% below the high.
SAR 12.97+SAR 0.27 (+2.13%)
Specialized Medical Company’s quoted price sits in the lower half of its reported 52-week range, 39.65% below the high.
SAR 23.65-SAR 0.43 (-1.79%)
Middle East Healthcare Company’s quoted price sits in the lower half of its reported 52-week range, 54.08% below the high.
SAR 22.00+SAR 0.02 (+0.09%)
Naba Alsaha Medical Services Company’s quoted price sits in the lower half of its reported 52-week range, 28.92% below the high.
